Isolated IgA Anti-β 2 Glycoprotein I Antibodies in Patients with Clinical Criteria for Antiphospholipid Syndrome
Open accessAbstract
Seronegative antiphospholipid syndrome (SNAPS) is an autoimmune disease present in patients with clinical manifestations highly suggestive of Antiphospholipid Syndrome (APS) but with persistently negative consensus antiphospholipid antibodies (a-PL). IgA anti-β 2 Glycoprotein I (aB2-GPI) antibodies are associated with APS. However, they are not currently considered to be laboratory criteria due to the heterogeneity of published works and the use of poor standardized diagnostic systems. We have aimed to assess aPL antibodies in a group of patients with clinical manifestations of APS (C-APS) to evaluate the importance of the presence of IgA aB2GPI antibodies in APS and its relation with other aPL antibodies. Only 14% of patients with C-APS were positive for any consensus antibody, whereas the presence of isolated IgA aB2GPI antibodies was found in 22% of C-APS patients. In patients with arterial thrombosis IgA aB2GPI, antibodies were the only aPL antibodies present. Serologic profile in primary APS (PAPS) is different from systemic autoimmune disorders associated APS (SAD-APS). IgA aB2GPI antibodies are more prevalent in PAPS and IgG aB2GPI antibodies are predominant in SAD-APS. The analysis of IgA aB2GPI antibodies in patients with clinical manifestations of PAPS might avoid underdiagnosed patients and provide a better diagnosis in patients with SAD-APS. Laboratory consensus criteria might consider including analysis of IgA aB2GPI for APS diagnosis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Anti-β2-glycoprotein I IgA is a risk factor for the development of APS thrombosis.
“Recent publications have confirmed that anti-β2-glycoprotein I IgA is a risk factor for the development of APS thrombosis [17–20].”
From Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus (2021) · cites this paper as [20]
The Results (§3.3; page unavailable) report a strong association between IgA antibody positivity and arterial thrombosis in patients meeting clinical APS criteria. But this was a cross-sectional study, and the Discussion (§4; page unavailable) says prospective studies are needed to establish whether the antibodies predict vascular or thromboembolic events. The paper therefore does not confirm that they are a risk factor for the development of thrombosis. (LLM, conf=0.86)
Experimental — accuracy not yet measuredIgA anti-β2-glycoprotein I antibodies in secondary APS patients showed better utility than that provided by the IgM isotype.
“IgA anti-β2-glycoprotein I antibodies in secondary APS patients showed better utility than that provided by the IgM isotype [20].”
From Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus (2021) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 41 · Cited by 59
- Authors
- Ruiz-García, R., Serrano, M., Ángel Martínez-Flores, J., Mora, S., Morillas, L., Martín-Mola, M. Á., Morales, J. M., Paz-Artal, E., & Serrano, A.
- Affiliations
- Servicio de Inmunología, Instituto de Investigación Hospital Universitario 12 de Octubre, Avenida Córdoba s/n, 28041 Madrid, Spain
- Research Institute Hospital 12 de Octubre (ES)
- Universidad San Pablo CEU (ES)
- Corresponding author
- Serrano, Antonio
- Venue
- Journal of Immunology Research
- Publisher
- Hindawi Limited
- Published
- 2014
- Volume
- 2014
- Pages
- 1-8
- ISSN
- 2314-7156 (ISSN-L)
- 2314-8861
- PMC
- PMC3987939
- OpenAlex
- W2015878170
- Cited by
- 59
- References
- 41
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 3 · 2022: 5 · 2021: 7 · 2020: 10 · 2019: 4 · 2018: 6 · 2017: 6 · 2016: 9 · 2015: 3 · 2014: 2
- FWCI
- 5.53
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal of Immunology Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Vasculitis and related conditions
- Health Sciences › Medicine › Pathology and Forensic Medicine › Systemic Sclerosis and Related Diseases
- Keywords
- seronegative antiphospholipid syndrome, antiphospholipid antibodies, primary antiphospholipid syndrome, arterial thrombosis, diagnostic criteria, antibody heterogeneity
- MeSH terms
- Carotid Artery Thrombosis, Female, Humans, Immunoglobulin A, Male, Middle Aged, Antiphospholipid Syndrome, Antibodies, Antiphospholipid, Venous Thrombosis, beta 2-Glycoprotein I
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
